Alto Neuroscience, Inc.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for central nervous system disorders. The company's pipeline consists of five product candidates targeting psychiatric and cognitive conditions. ALTO-100 is in Phase 2b development for bipolar depression, while ALTO-300, a melatonergic agonist and serotonergic antagonist, is in Phase 2b trials for major depressive disorder. The company is also advancing ALTO-101, a phosphodiesterase 4 inhibitor in Phase 2 proof-of-concept studies for cognitive impairment in schizophrenia; ALTO-203, a histamine H3 receptor inverse agonist in Phase 2 trials for depression with anhedonia; and ALTO-202, an NMDA receptor antagonist in Phase 1 development for major depressive disorder.

As a clinical-stage company, Alto Neuroscience does not generate meaningful revenue from product sales. The organization is currently funded through capital raises and operates with a lean structure of 76 full-time employees from its headquarters in Mountain View, California. The company was incorporated in Delaware in 2019 and is publicly listed on the New York Stock Exchange.